Elabela在子痫前期中的研究进展

doi:10.12280/gjfckx.20210746

摘要/Abstract

摘要：

子痫前期是孕产妇及新生儿死亡的主要原因之一,目前其发病机制仍不清楚。Elabela是一种新发现的Apelin受体（APJ）的内源性配体。Elabela和Apelin共有少量的类似序列,表现出相似的生物学作用,参与人类多种疾病的发生,如急性肾损伤、心力衰竭、糖尿病、高血压、胎儿发育异常和肿瘤等。与APJ的第一个配体Apelin相比,Elabela在孕妇的血清、胎盘、尿液及胎儿脐带血中均有表达。Elabela参与胚胎心血管系统的形成和胎盘的早期发育,在子痫前期的发病中发挥关键作用。综述Elabela的结构、生物学功能及其与子痫前期发病的关系,并探讨Elabela参与子痫前期发病的可能机制,包括参与胎盘滋养细胞侵袭、血管生成和损伤母体血管内皮细胞。

关键词: 先兆子痫, 高血压, 受体,血管紧张素,1型, 胎盘, 新生血管化,生理性, Elabela

Abstract:

Pre-eclampsia is one of the main causes of maternal and neonatal death. At present, the pathogenesis is still unclear. Elabela is a newly discovered endogenous peptide ligand of Apelin receptor (APJ). Elabela and Apelin have a small number of similar sequences, showing similar biological effects, which are involved in many kinds of human diseases, such as acute kidney injury, heart failure, diabetes, hypertension, fetal dysplasia, tumor and so on. Compared with Apelin, the first ligand of APJ, Elabela can be detected in maternal serum, placenta, urine and fetal umbilical cord blood. Elabela participates in the formation of embryonic cardiovascular system and the early development of placenta, and plays a key role in the pathogenesis of pre-eclampsia. In this review, we summarize the structure and biological function of Elabela and its relationship with the pathogenesis of pre-eclampsia, and discusses the possible mechanism of Elabela′s involvement in the pathogenesis of pre-eclampsia, including the invasion of placental trophoblast, angiogenesis and damage to maternal vascular endothelial cells.

Key words: Pre-eclampsia, Hypertension, Receptor,angiotensin,type 1, Placenta, Neovascularization,physiologic, Elabela

王丽静, 王富荣, 孙娴莉, 李园美, 董瑞峰. Elabela在子痫前期中的研究进展[J]. 国际妇产科学杂志, 2022, 49(2): 121-124.

WANG Li-jing, WANG Fu-rong, SUN Xian-li, LI Yuan-mei, DONG Rui-feng. Research Progress of Elabela in Pre-Eclampsia[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 121-124.

参考文献 27

[1]	Karatza AA, Dimitriou G. Preeclampsia Emerging as a Novel Risk Factor for Cardiovascular Disease in the Offspring[J]. Curr Pediatr Rev, 2020, 16(3):194-199. doi: 10.2174/1573396316666191224092405. doi: 10.2174/1573396316666191224092405
[2]	Yu P, Ma S, Dai X, et al. Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signaling[J]. Am J Transl Res, 2020, 12(8):4467-4477.
[3]	E Davies J, Pollheimer J, Yong HE, et al. Epithelial-mesenchymal transition during extravillous trophoblast differentiation[J]. Cell Adh Migr, 2016, 10(3):310-321. doi: 10.1080/19336918.2016.1170258. doi: 10.1080/19336918.2016.1170258
[4]	Huang SK, Shin K, Sarker M, et al. Apela exhibits isoform- and headgroup-dependent modulation of micelle binding, peptide conformation and dynamics[J]. Biochim Biophys Acta Biomembr, 2017, 1859(5):767-778. doi: 10.1016/j.bbamem.2017.01.028. doi: 10.1016/j.bbamem.2017.01.028
[5]	Liu Y, Wang L, Shi H. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia[J]. Hypertens Res, 2019, 42(7):928-934. doi: 10.1038/s41440-018-0193-3. doi: 10.1038/s41440-018-0193-3
[6]	Ma Z, Song JJ, Martin S, et al. The Elabela-APJ axis: a promising therapeutic target for heart failure[J]. Heart Fail Rev, 2021, 26(5):1249-1258. doi: 10.1007/s10741-020-09957-5. doi: 10.1007/s10741-020-09957-5
[7]	Ho L, Tan SY, Wee S, et al. ELABELA Is an Endogenous Growth Factor that Sustains hESC Self-Renewal via the PI3K/AKT Pathway[J]. Cell Stem Cell, 2015, 17(4):435-447. doi: 10.1016/j.stem.2015.08.010. doi: 10.1016/j.stem.2015.08.010
[8]	Panaitescu B, Romero R, Gomez-Lopez N, et al. ELABELA plasma concentrations are increased in women with late-onset preeclampsia[J]. J Matern Fetal Neonatal Med, 2020, 33(1):5-15. doi: 10.1080/14767058.2018.1484089. doi: 10.1080/14767058.2018.1484089 pmid: 29890874
[9]	Yang X, Bian Y, Wan J, et al. Variants in the 5′-UTR of APELA gene in women with preeclampsia[J]. Prenat Diagn, 2019, 39(4):308-313. doi: 10.1002/pd.5431. doi: 10.1002/pd.5431
[10]	Deniz R, Baykus Y, Ustebay S, et al. Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns[J]. J Obstet Gynaecol, 2019, 39(7):907-912. doi: 10.1080/01443615.2019.1572727. doi: 10.1080/01443615.2019.1572727
[11]	Wang L, Zhang Y, Qu H, et al. Reduced ELABELA expression attenuates trophoblast invasion through the PI3K/AKT/mTOR pathway in early onset preeclampsia[J]. Placenta, 2019, 87:38-45. doi: 10.1016/j.placenta.2019.08.077. doi: 10.1016/j.placenta.2019.08.077
[12]	Zhou L, Sun H, Cheng R, et al. ELABELA, as a potential diagnostic biomarker of preeclampsia, regulates abnormally shallow placentation via APJ[J]. Am J Physiol Endocrinol Metab, 2019, 316(5):E773-E781. doi: 10.1152/ajpendo.00383.2018. doi: 10.1152/ajpendo.00383.2018
[13]	Li Y, Yang X, Ouyang S, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: A preliminary study[J]. Clin Exp Hypertens, 2020, 42(3):239-243. doi: 10.1080/10641963.2019.1619756. doi: 10.1080/10641963.2019.1619756
[14]	Huang R, Zhu J, Zhang L, et al. Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy?[J]. Pregnancy Hypertens, 2019, 17:226-232. doi: 10.1016/j.preghy.2019.06.007. doi: S2210-7789(18)30759-1 pmid: 31487645
[15]	Georgiadou D, Boussata S, Ranzijn W, et al. Peptide hormone ELABELA enhances extravillous trophoblast differentiation, but placenta is not the major source of circulating ELABELA in pregnancy[J]. Sci Rep, 2019, 9(1):19077. doi: 10.1038/s41598-019-55650-5. doi: 10.1038/s41598-019-55650-5 pmid: 31836787
[16]	Sağraç D, Şişli HB, Doğan A. Apelin Receptor Signaling During Mesoderm Development[J]. Adv Exp Med Biol, 2020, 1298:1-15. doi: 10.1007/5584_2020_567. doi: 10.1007/5584_2020_567
[17]	Gore AV, Monzo K, Cha YR, et al. Vascular development in the zebrafish[J]. Cold Spring Harb Perspect Med, 2012, 2(5):a006684. doi: 10.1101/cshperspect.a006684. doi: 10.1101/cshperspect.a006684
[18]	Xu C. The Elabela in hypertension, cardiovascular disease, renal disease, and preeclampsia: an update[J]. J Hypertens, 2021, 39(1):12-22. doi: 10.1097/HJH.0000000000002591. doi: 10.1097/HJH.0000000000002591
[19]	Liu W, Yan J, Pan W, et al. Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system[J]. Ann Transl Med, 2020, 8(5):243. doi: 10.21037/atm.2020.02.07. doi: 10.21037/atm.2020.02.07
[20]	del Toro R, Prahst C, Mathivet T, et al. Identification and functional analysis of endothelial tip cell-enriched genes[J]. Blood, 2010, 116(19):4025-4033. doi: 10.1182/blood-2010-02-270819. doi: 10.1182/blood-2010-02-270819
[21]	Zhou Q, Zhang K, Guo Y, et al. Elabela-APJ axis contributes to embryonic development and prevents pre-eclampsia in pregnancy[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(3):319-321. doi: 10.1093/abbs/gmx143. doi: 10.1093/abbs/gmx143
[22]	李佳雯, 郑小敏, 应豪, 等. 妊娠期高血压疾病与胎儿生长受限的相关性研究[J]. 国际妇产科学杂志, 2021, 48(2):182-185. doi: 10.12280/gjfckx.20200781. doi: 10.12280/gjfckx.20200781
[23]	Ho L, van Dijk M, Chye S, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice[J]. Science, 2017, 357(6352):707-713. doi: 10.1126/science.aam6607. doi: 10.1126/science.aam6607
[24]	Zhang J, Zhou Y, Wu C, et al. Characterization of the Apelin/Elabela Receptors(APLNR) in Chickens, Turtles, and Zebrafish: Identification of a Novel Apelin-Specific Receptor in Teleosts[J]. Front Endocrinol (Lausanne), 2018, 9:756. doi: 10.3389/fendo.2018.00756. doi: 10.3389/fendo.2018.00756
[25]	Sato T, Sato C, Kadowaki A, et al. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage[J]. Cardiovasc Res, 2017, 113(7):760-769. doi: 10.1093/cvr/cvx061. doi: 10.1093/cvr/cvx061
[26]	Laudermilk LT, Harper KM, Moy SS, et al. Aplnr knockout mice display sex-specific changes in conditioned fear[J]. Behav Brain Res, 2021, 400:113059. doi: 10.1016/j.bbr.2020.113059. doi: 10.1016/j.bbr.2020.113059 pmid: 33309737
[27]	Chen Z, Wu C, Liu Y, et al. ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway[J]. Cell Death Dis, 2020, 11(8):698. doi: 10.1038/s41419-020-02912-0. doi: 10.1038/s41419-020-02912-0